INTRODUCTION:
The widespread use of cross-sectional imaging has led to the incidental discovery of many renal tumors (1). However, triage of therapies is currently difficult due to our inability to reliably differentiate benign from malignant, or indolent from aggressive renal tumors noninvasively by conventional imaging techniques. Hyperpolarized (HP) 13 C MR is a new metabolic imaging technique that highlights the increased glycolysis in many aggressive and metastatic cancers. This technique has already been successfully applied to the evaluation of prostate cancer presence and aggressiveness in animal models (2,3) and a clinical trial of hyperpolarized 13 C MR in patients with prostate cancer is currently underway. HP 13 C MR may similarly provide an excellent opportunity to characterize renal tumor aggressiveness in vivo. In this study, we aim to test the hypothesis that HP 13 C MR can differentiate among normal renal tubule epithelial cells, indolent renal cell carcinoma (RCC), and aggressive/metastatic RCC in cell culture.
METHODS:
Cell lines: HK2 (normal human renal tubule epithelial cell line), UMRC6 (localized non-metastatic human RCC cell line), and UOK262 (highly aggressive and metastatic human RCC cell line) (4), with doubling times 85, 45, and 24 hours respectively, were grown in DMEM medium. C]pyruvate and 1mM unlabelled glucose at 37°C for 120 min, followed by washing and trypsinization. Cell pellets (n=3, per cell line) and cell media were analyzed in custom designed 35μL ZrO 2 rotors containing 3.0μl D 2 O + 0.75% TSP. HR-MAS data were acquired at 11.7T, 1°C, and 2,250 Hz spin rate using a Varian INOVA spectrometer, equipped with a 4mm gHX nanoprobe. Quantitative 1D 1 H spectra were acquired with 40,000 points, 20,000 Hz spectral width, and 256 transients (at = 2s, T R = 6s). C decoupling (at=0.82s, nt=8, ni=128, T R =3.8s), as previously described [7] , and statistically compared using a students t-test (p< 0.05). Assessment of Metabolic Fluxes -HP 13 C Bioreactor Studies: Cells were encapsulated as described previously (8). The encapsulated cells were then maintained in a custom designed 10mm NMR-compatible bioreactor system, with a continuous flow of 37°C DMEM media oxygenated with 95% Air/5% CO 2 . 1mL of 4mM HP [1-
13 C] pyruvate (Hypersense TM , Oxford Instrument) was injected into the bioreactor.
13 C NMR spectra were acquired at 3sec intervals using 10° pulses for 300sec on a 11.7T Varian INOVA (Varian Instruments) equipped with a 10mm direct detect broadband probe. Both prior to and after injection, cell viability was assessed by measuring β-NTP peak areas from 31 P spectra (90° pulse nt=1024, at=1sec, 1 hour). The relative integrals of pyruvate and lactate were plotted as a function of time to determine maximum flux to lactate for each of the three cell lines. 
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